VBI Vaccines Inc.: VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022
Presentation title: "Long-Term Persistence of Anti-HBs Antibodies after Vaccination with a 3-Antigen HBV Vaccine Compared with a Single-Antigen HBV Vaccine" VBI Vaccines Inc. (Nasdaq: VBIV) (VBI)